Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 9/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.53 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629606 | 0.95 | PIK3CB (1.00) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6625427 | 0.95 | PIK3CB (1.00) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6626232 | 0.89 | PIK3CB (0.70) | PIK3CBALDH1A1KDM4EPIK3CDLCK | |
| SCHEMBL20078072 | 0.88 | PIK3CB (0.87) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6626404 | 0.88 | PIK3CB (0.87) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL927196 | 0.88 | PIK3CB (0.87) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6626263 | 0.87 | PIK3CB (0.85) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6625463 | 0.87 | PIK3CB (0.85) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3C2B | |
| SCHEMBL6627240 | 0.87 | PIK3CB (0.85) | PIK3CBALDH1A1KDM4EPIK3CDPIK3CA | |
| SCHEMBL6625296 | 0.86 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (GB) | 2010-01-28 | — | — | US | disclosed |
| EP-2069330-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008032028-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032041-A1 | PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST PI3K ENZYMES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1020462-B1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2004-02-11 | — | — | EP | disclosed |
| US-6251900-B1 | Heterocyclic compounds and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2001-06-26 | — | — | US | disclosed |
| CN-1271355-A | Heterocyclic compounds and antitumor agent containing the same as active ingredient | ZENYADKU KOGYO K K (JP) | 2000-10-25 | — | — | CN | disclosed |
| EP-1020462-A1 | HETEROCYCLIC COMPOUNDS AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MTOR, PIK3CA, PIK3CD | PIK3CB 13/4885ALDH1A1 2727/4885KDM4E 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.